Xin Wei Wang, PhD, on New Blood Test Able to Identify Those Likely to Develop HCC

Video

The co-leader of the NCI Center for Cancer Research Liver Cancer Program discussed the clinical utility of the blood test and how it could potentially change liver cancer diagnoses moving forward.

According to study results published in Cell, researchers have developed a new blood test that may help identify individuals who are likely to develop hepatocellular carcinoma (HCC).

In this study, investigators profiled serological samples from 899 individuals currently enrolled in a National Cancer Institute-University of Maryland (NCI-UMD) case-control study of liver cancer, including 150 who had HCC. They then used a synthetic virome technology, titled VirScan, to detect the exposure history of these individuals to more than 1000 human viruses.

Using this high-throughput method, researchers developed a unique viral exposure signature (VES) that could discriminate HCC cases from at-risk or healthy volunteers. They then validated this signature in a prospective cohort of 173 individuals with chronic liver disease who were part of a 20-year study. During that time, 44 of the participants developed HCC.

In an interview with CancerNetwork®, study leader Xin Wei Wang, PhD, co-leader of the NCI Center for Cancer Research Liver Cancer Program, spoke about the use of the blood test and how it could potentially change liver cancer diagnoses moving forward.

“Blood tests provide a so-called less-invasive or non-invasive approach to detect a cancer, [so] obviously blood tests are the ideal method for screening patients for signs of cancer,” Wang explained.

Though the test is still in its early stages of development, Wang indicated that this approach has the possibility to be utilized in other cancer spaces as well.

“We are planning to apply this approach to other cancer types,” said Wang. “At least for now that includes cholangiocarcinoma, another liver cancer type due to liver fluke infection, and prostate cancer, especially those for individuals with African descent.”

This segment comes from the CancerNetwork® portion of the MJH Life Sciences National Broadcast, airing daily on all MJH Life Sciences channels.

Reference:

Liu J, Tang W, Budhu A, et al. A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma. Cell. doi:10.1016/j.cell.2020.05.038.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content